Expanding Access to Care: New Biosimilars Now Available

The specialty pharmaceutical portfolio available at Prodigy Health has expanded with the addition of Pfizer’s biosimilar therapies, supporting broader access to critical treatments across oncology, immunology, hematology, and supportive care.

The expanded portfolio now includes Abrilada™ (adalimumab-afzb), Inflectra® (infliximab-dyyb), Ruxience® (rituximab-pvvr), Trazimera® (trastuzumab-qyyp), Zirabev® (bevacizumab-bvzr), Retacrit® (epoetin alfa-epbx), and Nivestym® (filgrastim-aafi), each developed to meet rigorous standards for safety, efficacy, and quality equivalent to their reference biologics.

Biosimilars represent a critical advancement in healthcare, offering comparable clinical outcomes while improving affordability and access to treatment. Designed to match reference products with no clinically meaningful differences, biosimilars support the sustainability of healthcare delivery and enable broader patient access to life-changing therapies.

‍